Sign In
Buy ACET
$7.83
-0.280 (-3.45%)
At Close: Jun 03, 2026
Are Medical Stocks Lagging Adicet Bio (ACET) This Year?
10:40am, Thursday, 28'th May 2026
Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Wall Street Analysts Believe Adicet Bio (ACET) Could Rally 319.64%: Here's is How to Trade
10:56am, Monday, 25'th May 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 319.6% in Adicet Bio (ACET). While the effectiveness of this highly sought-after metric is questionable, the po
Adicet Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
04:01pm, Wednesday, 13'th May 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease
Adicet Bio (ACET) Upgraded to Buy: Here's Why
01:01pm, Tuesday, 24'th Mar 2026
Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
04:00pm, Thursday, 12'th Mar 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease
Brokerages Set Adicet Bio, Inc. (NASDAQ:ACET) PT at $69.00
01:10am, Thursday, 05'th Mar 2026
Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat.com repo
Adicet Bio, Inc. (NASDAQ:ACET) Receives $69.00 Consensus PT from Brokerages
01:32am, Sunday, 08'th Feb 2026
Shares of Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat reports. One resear
Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
07:00am, Friday, 30'th Jan 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease
Adicet Bio (NASDAQ:ACET) Shares Pass Below 200-Day Moving Average – What’s Next?
02:29am, Tuesday, 20'th Jan 2026
Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $11.11 and
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Down 95.7% in December
02:06am, Wednesday, 14'th Jan 2026
Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 642,
Adicet Bio (NASDAQ:ACET) Stock Passes Below Two Hundred Day Moving Average – Should You Sell?
03:55am, Thursday, 08'th Jan 2026
Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $11.22 and traded as low as $8.07. Adic
Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones
07:00am, Wednesday, 07'th Jan 2026
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease
Adicet Bio, Inc. (NASDAQ:ACET) Short Interest Update
02:55am, Tuesday, 30'th Dec 2025
Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 14,910,58
Adicet Bio Announces Reverse Stock Split
08:30am, Friday, 26'th Dec 2025
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune disease
Adicet Bio (NASDAQ:ACET) Shares Cross Below Two Hundred Day Moving Average – Time to Sell?
03:12am, Thursday, 25'th Dec 2025
Shares of Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) crossed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $0.72 and traded as low as $
